TRCT
CAPR icon

Tower Research Capital (TRC)’s Capricor Therapeutics CAPR Stock Holding History

Tower Research Capital (TRC)’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$68.7K Sell
2,853
-5,452
-66% -$165K ﹤0.01% 2498
2026
Q1 		$252K Buy
8,305
+7,178
+637% +$191K 0.01% 1436
2025
Q4 		$32.5K Sell
1,127
-3,126
-74% -$40.8K ﹤0.01% 2747
2025
Q3 		$30.7K Sell
4,253
-2,495
-37% -$18.4K ﹤0.01% 2917
2025
Q2 		$67K Buy
6,748
+4,976
+281% +$52.6K ﹤0.01% 2720
2025
Q1 		$16.8K Sell
1,772
-4,425
-71% -$61.4K ﹤0.01% 3142
2024
Q4 		$85.5K Sell
6,197
-17,627
-74% -$309K ﹤0.01% 2239
2024
Q3 		$362K Buy
23,824
+14,300
+150% +$70.7K 0.01% 1097
2024
Q2 		$45.4K Buy
9,524
+4,691
+97% +$26.2K ﹤0.01% 3182
2024
Q1 		$32.8K Buy
4,833
+3,473
+255% +$16.8K ﹤0.01% 2579
2023
Q4 		$6.65K Sell
1,360
-7,562
-85% -$24.6K ﹤0.01% 4716
2023
Q3 		$30.5K Sell
8,922
-3,314
-27% -$18.6K ﹤0.01% 3007
2023
Q2 		$58.5K Buy
12,236
+3,466
+40% +$15.2K ﹤0.01% 2467
2023
Q1 		$37K Buy
8,770
+5,096
+139% +$21.9K ﹤0.01% 2777
2022
Q4 		$14K Buy
+3,674
New +$17.5K ﹤0.01% 3492
2022
Q3 		– Sell
-1,684
Closed -$5K – 6087
2022
Q2 		$5K Buy
+1,684
New +$5.98K ﹤0.01% 5036
2022
Q1 		– Sell
-1,277
Closed -$4K – 6116
2021
Q4 		$4K Buy
1,277
+1,259
+6,994% +$4.41K ﹤0.01% 5283
2021
Q3 		$0 Sell
18
-14,284
-100% -$65K ﹤0.01% 5787
2021
Q2 		$73K Buy
14,302
+7,109
+99% +$30.1K ﹤0.01% 2686
2021
Q1 		$34K Buy
7,193
+6,171
+604% +$35.5K ﹤0.01% 3441
2020
Q4 		$4K Buy
+1,022
New +$4.43K ﹤0.01% 4689
2016
Q4 		– Sell
-57
Closed -$2K – 3840
2016
Q3 		$2K Sell
57
-20
-26% -$752 ﹤0.01% 3033
2016
Q2 		$3K Sell
77
-68
-47% -$2.4K ﹤0.01% 3664
2016
Q1 		$4K Sell
145
-102
-41% -$2.47K ﹤0.01% 2855
2015
Q4 		$8K Buy
+247
New +$9.83K ﹤0.01% 2383
2015
Q3 		– Sell
-2
Closed – – 4042
2015
Q2 		$0 Hold
2
– – ﹤0.01% 4417
2015
Q1 		$0 Buy
+2
New +$173 ﹤0.01% 4419

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Tower Research Capital (TRC)'s CAPR Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Capricor Therapeutics (CAPR) stake by 66% in Q2 2026, selling an estimated $165K and leaving 2,853 shares worth $68.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2498.

Tower Research Capital (TRC) first reported a position in CAPR in Q1 2015 and has held it in 27 quarters since. The position peaked at $362K in Q3 2024. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Tower Research Capital (TRC) held 2,853 shares of Capricor Therapeutics worth $68.7K as of Q2 2026.
  • Tower Research Capital (TRC) sold 5,452 Capricor Therapeutics shares in Q2 2026, an estimated $165K.
  • Capricor Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2498 holding.
  • Tower Research Capital (TRC) first reported a position in Capricor Therapeutics in Q1 2015 and has held it in 27 quarters since.
  • Tower Research Capital (TRC)'s Capricor Therapeutics position peaked at $362K in Q3 2024.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.